Clinical Trial

A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-1484 administered as monotherapy and in combination with pembrolizumab (MK-3475) in adults with advanced or metastatic solid tumors.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-07-31 -> 2026-09-30 2026-08-11
minor Completion pushed: 2026-07-31 -> 2026-09-30 2026-08-11
Trial Details
NCT Number NCT05382325
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Advanced or Metastatic Solid Tumors
Enrollment 70 participants
Start Date 2022-06-16
Primary Completion 2026-09-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-10